JANX Company Profile and Key Details

Q: Who are the executives of JANX?

Ms. Brenda Van VreeswykHead of HRMr. Tighe M. Reardon C.F.A., C.P.A., CPAActing Chief Financial OfficerDr. David Alan Campbell Ph.D.Pres, Chief Executive Officer & DirectorDr. Wayne Godfrey M.D.Chief Medical OfficerMr. Tommy Diraimondo Ph.D.Senior Director of ResearchMr. Tighe M. Reardon C.F.A., CPA, CPAActing Chief Financial OfficerMr. James PenningtonGen. CounselMr. Charles M. WinterSenior Vice President of Chemistry, Manufacturing & ControlsMr. Andy Hollman MeyerChief Bus. OfficerMr. Byron Robinson J.D., Ph.D.Chief Strategy Officer

NASDAQ : JANX

Janux Therapeutics

$15.57

0.24+1.57%

At Close 4:00 PM

59.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Janux Therapeutics, Inc. (JANX) stock surged +1.57%, trading at $15.57 on NASDAQ, up from the previous close of $15.33. The stock opened at $15.59, fluctuating between $15.29 and $15.95 in the recent session.

Stock Snapshot

15.33

Prev. Close

949.53M

Market Cap

15.29

Day Low

-8.46

P/E Ratio

-1.84

EPS (TTM)

-1.12

Cash Flow per Share

15.59

Open

60.98M

Number of Shares

15.95

Day High

90%

Free Float in %

7.38

Book Value

1.4M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 27, 2026	15.60	15.95	15.29	15.57	1.4M
Jul 24, 2026	15.81	15.87	15.24	15.33	550.01K
Jul 23, 2026	15.41	15.79	15.26	15.72	931.62K
Jul 22, 2026	16.26	16.36	15.53	15.62	950.76K
Jul 21, 2026	15.98	16.30	15.88	16.26	710.89K
Jul 20, 2026	16.46	16.53	16.04	16.05	804.69K
Jul 17, 2026	15.76	16.39	15.65	16.26	805.83K
Jul 16, 2026	15.93	16.11	15.72	15.84	648.06K
Jul 15, 2026	15.83	16.16	15.50	16.03	846.65K
Jul 14, 2026	16.10	16.35	15.77	15.78	847.32K
Jul 13, 2026	16.24	16.36	15.87	16.14	800.96K
Jul 10, 2026	16.77	16.83	15.97	16.40	832.73K
Jul 09, 2026	16.56	16.91	16.54	16.75	902.25K
Jul 08, 2026	15.90	16.68	15.70	16.66	1.36M
Jul 07, 2026	15.67	16.25	15.62	16.15	1.29M
Jul 06, 2026	15.54	15.72	15.22	15.41	607.45K
Jul 02, 2026	14.85	15.59	14.64	15.54	1.04M
Jul 01, 2026	15.48	15.64	14.61	14.66	1.61M
Jun 30, 2026	15.34	15.81	15.26	15.36	1.22M
Jun 29, 2026	15.02	15.35	14.64	15.33	1.19M

Contact Details

San Diego, CA 92037

United States

https://www.januxrx.com 858 750 4700

About Company

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Stock Peers

ARGX

-29.4-3.20%

argenx SE$888.82 REGN

11.16+1.70%

Regeneron Pharmaceuticals, Inc.$667.17 MDGL

6.74+1.24%

Madrigal Pharmaceuticals, Inc.$551.25 UTHR

-0.53-0.10%

United Therapeutics Corporation$527.94 VRTX

1.64+0.34%

Vertex Pharmaceuticals Incorporated$479.00 KRYS

16.63+4.96%

Krystal Biotech, Inc.$351.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

BeOne Medicines AG$325.90 PRAX

-9.5-2.92%

Praxis Precision Medicines, Inc.$315.80 LGND

-3.03-1.01%

Ligand Pharmaceuticals Incorporated$297.50

Frequently Asked Questions

What is the current Janux Therapeutics, Inc. (JANX) stock price?

Janux Therapeutics, Inc. (NASDAQ: JANX) stock price is $15.57 in the last trading session. During the trading session, JANX stock reached the peak price of $15.95 while $15.29 was the lowest point it dropped to. The percentage change in JANX stock occurred in the recent session was 1.57% while the dollar amount for the price change in JANX stock was $0.24.

JANX's industry and sector of operation?

The NASDAQ listed JANX is part of Biotechnology industry that operates in the broader Healthcare sector. Janux Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of JANX?

Ms. Brenda Van Vreeswyk
Head of HR
Mr. Tighe M. Reardon C.F.A., C.P.A., CPA
Acting Chief Financial Officer
Dr. David Alan Campbell Ph.D.
Pres, Chief Executive Officer & Director
Dr. Wayne Godfrey M.D.
Chief Medical Officer
Mr. Tommy Diraimondo Ph.D.
Senior Director of Research
Mr. Tighe M. Reardon C.F.A., CPA, CPA
Acting Chief Financial Officer
Mr. James Pennington
Gen. Counsel
Mr. Charles M. Winter
Senior Vice President of Chemistry, Manufacturing & Controls
Mr. Andy Hollman Meyer
Chief Bus. Officer
Mr. Byron Robinson J.D., Ph.D.
Chief Strategy Officer

How JANX did perform over past 52-week?

JANX's closing price is 28.46% higher than its 52-week low of $12.12 where as its distance from 52-week high of $35.34 is -55.94%.

How many employees does JANX have?

Number of JANX employees currently stands at 109.

Link for JANX official website?

Official Website of JANX is: https://www.januxrx.com

How do I contact JANX?

JANX could be contacted at phone 858 750 4700 and can also be accessed through its website. JANX operates from 10955 Vista Sorrento Parkway, San Diego, CA 92037, United States.

How many shares of JANX are traded daily?

JANX stock volume for the day was 1.4M shares. The average number of JANX shares traded daily for last 3 months was 1.08M.

What is the market cap of JANX currently?

The market value of JANX currently stands at $949.53M with its latest stock price at $15.57 and 60.98M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	109
Beta	2.51
Sales or Revenue	$8.08M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	109
Beta	2.51
Sales or Revenue	$8.08M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

JANX Company Profile and Key Details

Janux Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Valuation Metrics

Company Overview

Price Forecast & Outlook

Key Takeaways